Introduction {#s1}
============

Clinical guidelines are useful tools for making clinical management more efficient, and for assisting physicians in making decisions based on scientific data and expert opinion \[[@R01],[@R02]\]. However, whether these guidelines result in actual improvement in clinical care and outcomes is unclear. Wide variability in improvements after guideline implementation limits generalizability. A unique situation arises when a drug in common clinical use is associated with higher risk of morbidity and mortality and a more efficient alternative does not exist. Aprotinin, an unquestionably efficient antifibribolytic agent, commonly used in cardiac surgery was reported to be associated with higher risk of short and long-term mortality. While its efficacy as a hemostatic agent was never doubted, its negative safety profile prompted new questions about its continued use (http://www.fda.gov/cder/drug/advisory/aprotinin.htm. Accessed May 7, 2007).

In early 2006, two studies on the risk of aprotinin in cardiac surgery \[[@R03],[@R04]\] prompted the US Food and Drug Administration (FDA) to issue an advisory on its use. These publications generated significant concern within the scientific community and among the lay public about the risks associated with a previously approved drug that was routinely used in cardiac surgery. In response to these concerns, and other evidence suggesting its efficacy in specific situations \[[@R05]\], we assembled a team of experts within the institution to create guidelines for the appropriate use of aprotinin in cardiothoracic surgery. We report the basis for creating these guidelines, as well as the implementation and follow up process, patterns of change in use of aprotinin in our institution, and resulting change in outcomes, specifically acute kidney injury (AKI) and postoperative bleeding.

Methods {#s2}
=======

Based on available evidence from randomized trials and observational studies on aprotinin and other antifibrinolytics in a variety of surgical settings, we proposed a three-tiered system for using aprotinin (*Table 1*).
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Category A included those surgeries in which patients are at high risk of bleeding/transfusion, and available evidence indicated that the use of aprotinin is beneficial in modifying that risk. Category B included those surgeries associated with a higher than normal risk of bleeding/transfusion, and that aprotinin use may be beneficial in reducing that risk. The guidelines stated that the decision to use aprotinin in these patients should be made on a case-by-case basis taking into account the potential benefits and risks of aprotinin administration. Category C included those cases where the risk of bleeding/transfusion was not higher than normal and that available evidence did not definitively support the use of aprotinin. In addition, two special patient categories were identified: those that refuse transfusion of blood products, and those with re-exposure to aprotinin. For the first special category, aprotinin use was considered beneficial in a setting where treatment of bleeding was not an option, e.g. Jehovah's Witness. Re-exposure to aprotinin was not recommended if prior exposure to the drug occurred within the last six months.

Specific recommendations were made with regard to discussion and documentation with the patient regarding the use of aprotinin and options for patients who refuse the drug. Emergent cases in which discussion was not feasible required two team physicians to agree to the use of aprotinin with documentation of reasons for its use.

Guidelines were circulated among all anesthesia, surgery and pharmacy staff, and were posted on a special website accessible on all automated anesthesia workstations to enhance knowledge of the guidelines and education on FDA concerns regarding the drug.

The process was also approved by the institutional risk management and pharmacy committees. Data was gathered with Duke University Medical Center Institutional Review Board approval on all cases where aprotinin was used. Patients in whom aprotinin was used were categorized as noted in the guidelines.

Aprotinin use was quantified in each risk category. Sub-groups were made within each risk category according to reduction in aprotinin use. Comparisons were then made between these subgroups with regard to outcomes pre- and post-guideline implementation. In all cases that aprotinin was not used, aminocaproic acid was the default antifibrinolytic agent used.

AKI was defined using peak postoperative rise in serum creatinine relative to the preoperative baseline (%ΔCr). Mean %ΔCr was compared before and after guideline implementation with a simple t-test. A similar secondary analysis of subgroups with smaller reductions in aprotinin use (\<50% patients) was also performed.

Results {#s4}
=======

Aprotinin was used in 58.5% of all cardiac surgery cases (469 of a total 802 patients) before institution of guidelines from March 2005 to January 2006. Following guidelines institution, aprotinin was used in 19.7% of cases (151 out of 767 patients) from March 2006 to January 2007, representing a 67.8% reduction in usage. The greatest reduction in use was noted for category C indications (78%) followed by categories B (66%) and A (36%) (*Figure 1*).
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Although its use was discouraged for category C indications, aprotinin was used in some cases after consideration of risks and benefits by the operating team. The guidelines were reviewed after one year following new evidence \[[@R06]\] and the revised FDA warning on re-exposure anaphylaxis risk (http://www.fda.gov/medwatch/safety/2006/dec06.

htm\#Trasylol. Accessed on May 7, 2007). An electronic method of documentation was introduced to track compliance with guidelines and identify patients with previous exposure to aprotinin within the last 12 months per the revised FDA warning.

In the subset of groups with large reductions in aprotinin use (pre-guideline usage =82%, n=239; post-guidelines usage=17%, n=241) there was a significant decrease in postoperative AKI (%?Cr 43.8% vs. 31.7%, p=0.05; *figure 2*).
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In the secondary analysis of sub-groups with smaller reductions in aprotinin use (preguidelines

usage =49%, n=562; post-guidelines usage =23%, n=525) there was a non-significant reduction in AKI (%ΔCr 34.2 vs. 32.8%, p=0.76). Chest tube drainage showed a statistically insignificant increase in the lower risk categories.

Discussion {#s7}
==========

Our report highlights two issues: the response to a warning from a regulatory body, and the clinical effect of this response. We responded to new FDA warning regarding aprotinin with generating internal guidelines, implementing and disseminating information, and measuring outcomes as a result of this change in practice. This led to a significant overall reduction in usage of aprotinin with change in measured short-term outcomes. With regard to these outcomes, specifically, AKI, in this retrospective study, there was a significant decline in post-cardiac surgery AKI associated with reduced aprotinin use (vs, aminocaproic acid). Notably, this effect appeared unrelated to bleeding risk group (*Figure 2*) and was accompanied by greater chest tube drainage but not red cell transfusion. While the implementation of guidelines resulted in a change in outcomes, the overall effects of reduction in aprotinin use on long-term outcomes is still unclear. For instance, despite an increase in incidence of postoperative AKI in the higher bleeding risk groups, the impact on mortality or long-term renal outcomes remains unknown. In the higher risk sub-groups, the increase in AKI with no increase in chest tube drainage suggests that aprotinin use is associated with higher renal risk without the lower bleeding/transfusion benefit compared to aminocaproic acid. However, conclusions to be drawn from such a small dataset are limited, but do not support a rationale that aprotinin nephrotoxicity is offset by its hemostatic advantage over aminocaproic acid in high risk patients.

Wide variability in improvements in outcomes following implementation of clinical guidelines has been attributed to several reasons. Chief among them has been variability in implementation of guidelines themselves due to problems with dissemination of information, and/or lack of availability of resources to implement guidelines. Most often, efficient generation of guidelines with acceptance by all invested parties, comprehensive coverage of all clinical scenarios and dissemination of information have resulted in improvements in outcomes. In our report, we highlight most of these factors that led to successful response with measurable outcomes. Whether these improved longer-term outcomes is under continued investigation.

In summary, we report our institution's response to new data and FDA guidelines regarding potential risks of aprotinin, and the resulting change in outcomes as a result of this response. Our institution responded with the swift creation of guidelines based on expert review of current data, consensus among anesthesiologists, surgeons, pharmacists and administrators, and implementation of measurable tools to track compliance with guidelines. Aprotinin use was reduced after implementation of these guidelines, but more importantly, an evidence-based approach to the use of aprotinin was introduced, consistent with regulatory warnings and public concern. This resulted in a change in some short-term adverse outcomes. While aprotinin use is no longer recommended under any clinical situation, we feel that this model of guideline implementation can be useful in similar scenarios with other drugs.
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